@article{86ca3a205d2f45b392ea39528d5e3108,
title = "Deep residual inception encoder-decoder network for amyloid PET harmonization",
abstract = "Introduction: Multiple positron emission tomography (PET) tracers are available for amyloid imaging, posing a significant challenge to consensus interpretation and quantitative analysis. We accordingly developed and validated a deep learning model as a harmonization strategy. Method: A Residual Inception Encoder-Decoder Neural Network was developed to harmonize images between amyloid PET image pairs made with Pittsburgh Compound-B and florbetapir tracers. The model was trained using a dataset with 92 subjects with 10-fold cross validation and its generalizability was further examined using an independent external dataset of 46 subjects. Results: Significantly stronger between-tracer correlations (P <.001) were observed after harmonization for both global amyloid burden indices and voxel-wise measurements in the training cohort and the external testing cohort. Discussion: We proposed and validated a novel encoder-decoder based deep model to harmonize amyloid PET imaging data from different tracers. Further investigation is ongoing to improve the model and apply to additional tracers.",
keywords = "Alzheimer's disease, Centiloid, amyloid PET",
author = "Jay Shah and Fei Gao and Baoxin Li and Valentina Ghisays and Ji Luo and Yinghua Chen and Wendy Lee and Yuxiang Zhou and Benzinger, {Tammie L.S.} and Reiman, {Eric M.} and Kewei Chen and Yi Su and Teresa Wu",
note = "Funding Information: Yi Su was supported by NIH grants R01AG031581, R01AG069453, P30AG019610, and Arizona Department of Health Services (ADHS) and the State of Arizona, ADHS Grant No. CTR040636 in partial support of this research work; Yi Su was also supported by NIH grant R01AG055444, R01AG058468, U19AG024904, R42AG053149, R21AG065942, Alzheimer's Association AARG17532945, BrightFocus Foundation ADR A2017272S outside of this work; Yi Su also received consulting fees from Green Valley Pharmaceuticals, LLC. Fei Gao has a patent filing unrelated to this work: “Deep learning based blob detection systems and methods,” and serves as Director/Board Member of DAIS division, IISE (unpaid). Baoxin Li received grant funding outside of this work from Office of Navy Research, served as a consultant for the University of Oklahoma, and received an honorarium for an invited talk at Department of Homeland Security. Eric M. Reiman received NIH grants P30AG019610, U19AG024904, and funding from the State of Arizona in partial support of this research; Eric M. Reiman also received funding from NIH R01AG069453, R01AG031581, R01AG055444, R01AG058468, U01NS093334, OT2OD026549, P01AG052350, U54MD000507, U01AG016976, and R01AG054671, NOMIS Foundation, Gates Venture and State of Arizona; Eric M. Reiman is also a PI of public‐private partnerships that including funding from Roche, Novartis, and Cerveaux; Eric M. Reiman has been a compensated scientific advisor and/or received travel support from Alzheon, Aural Analytics, Denali, Green Valley, Retromer Therapeutics, and Vaxxinity; Eric M. Reiman also has received honoraria for presentations to several academic organizations; Eric M. Reiman is a co‐inventor of a pending patent related to the role of the APOE Christchurch variant in the treatment and prevention of Alzheimer's disease; Eric M. Reiman serves on the Flinn Foundation Board of Directors and is a co‐founder and shareholder of ALZPath, a start‐up company related to the advancement of blood‐based biomarkers in research, treatment development and care. Kewei Chen received funding from NIH and the State of Arizona in partial support of this research and outside of this work; Kewei Chen also served as paid consultant to Green Valley Pharmaceuticals, Beijing Normal University, and the Sixth People's Hospital in Shanghai; Kewei Chen has a patent linking multi‐modal data; Jay Shah, Valentina Ghisays, Ji Luo, Yinghua Chen, Wendy Lee, Yuxiang Zhou, Tammie L.S. Benzinger, and Teresa Wu have nothing further to disclose. Funding Information: The research is supported in part by R01AG031581, R01AG069453, P30AG019610, Arizona Department of Health Services (ADHS) and the State of Arizona, ADHS Grant No. CTR040636. The funding sources did not play a role in the study design, in the collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit the article for publication. Data were provided in part by OASIS‐3: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P50 AG005681, P30 NS098577, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV‐45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. Funding Information: The research is supported in part by R01AG031581, R01AG069453, P30AG019610, Arizona Department of Health Services (ADHS) and the State of Arizona, ADHS Grant No. CTR040636. The funding sources did not play a role in the study design, in the collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit the article for publication. Data were provided in part by OASIS-3: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P50 AG005681, P30 NS098577, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AV-45 doses were provided by Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2022",
month = dec,
doi = "10.1002/alz.12564",
language = "English",
volume = "18",
pages = "2448--2457",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
number = "12",
}